SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

[83] List et al. (2009) T2DM drug-naive patients ... Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis.

“Our study suggests that SGLT2 inhibitors may provide benefit in slowing ... Please see the original reference for a full list of disclosures. Bonnesen K, Heide-Jørgensen U, Christensen DH ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

Calquence total revenues increased 20% in the fourth quarter driven by sustained BTK inhibitor leadership in ... market leadership in the fast-growing SGLT2 class and see potential for increased ...

“Our study suggests that SGLT2 inhibitors may provide benefit in slowing the progression ... Please see the original reference for a full list of disclosures. Bonnesen K, Heide-Jørgensen U, ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly ... while Steglujan will cost $6,329 per year at list price. Steglatro and Steglujan will be available this month ...

SGLT2 inhibitor medications have steep retail prices ... with agreed discounts ranging from 38-79% off list price. In Palm Beach County, FL, where my fellowship is based, the Palm Beach County Medical ...